secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0001193125-23-286790
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion appoints Michael Higgins and Dina Katabi to Board of Directors; board expands to six members.
--------------------------------------------------------------------------------

- Board increased to six members; Higgins and Katabi elected effective Nov 30, 2023, both deemed independent under NASDAQ rules.
- Higgins appointed Audit Committee Chair; Katabi appointed to Nominating and Corporate Governance Committee.
- Higgins is Voyager Therapeutics Chairman and former Ironwood COO; Katabi is MIT professor, MacArthur Fellow, and co-founder of Emerald Innovations.
- Compensation: each receives $12,000 cash retainer and 20,000 restricted stock units vesting over 42 months.
- Press release signals board refresh to explore possible licenses, mergers, acquisitions, or other investments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/0001193125-23-286790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/d559453d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-286790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer